Becton Dickinson Issues Class I Correction for BD Spinal Trays After Huons Bupivacaine GMP Failure

A drug-component quality failure at a third-party manufacturer has forced a Class I-level field correction across Becton Dickinson's BD Spinal Tray product lines, a sequence that illustrates precisely how GMP deficiencies in a supplier's injectable drug operation can cascade into device supply chain disruptions. The FDA has classified this as its most serious correction category, citing risk of serious injury or death if affected trays are used without removing the implicated bupivacaine ampules.

The root cause traces to Huons Co., Ltd., the South Korean manufacturer supplying bupivacaine ampules incorporated into BD Spinal Trays. Quality issues identified during a recent FDA inspection, combined with limited reports of drug ineffectiveness, triggered a separate Huons bupivacaine recall. Because those ampules are co-packaged in BD's spinal anesthesia kits, the correction extends to three tray configurations: the BD Spinal Tray with BD Whitacre Needle, the BD Spinal Tray with BD Quincke Needle, and the BD Spinal Tray with Sprotte Needle. Risks associated with compromised injectable bupivacaine include localized infection, inflammatory response, and reduced anesthetic effectiveness in spinal, epidural, or nerve block procedures.

On April 27, Becton Dickinson notified all affected customers by letter. The corrective instruction is point-of-use removal: upon opening any affected tray, the bupivacaine ampule must be removed and destroyed before the procedure begins. All remaining tray components are cleared for continued use. Facilities are directed to secure an alternative local bupivacaine source prior to entering the procedural environment. As of the April 27 notification date, Becton Dickinson had reported no confirmed serious injuries or deaths linked to the affected ampules.

For pharma manufacturers supplying drug components within combination products or kits, the Huons-BD sequence is a direct read on supplier qualification obligations under 21 CFR Part 211 and ICH Q10. When a drug component is embedded in a device kit, a GMP inspection finding at the drug manufacturer does not stay contained within that manufacturer's quality system. It propagates upstream to every finished product incorporating that component, triggering correction obligations, customer notifications, and FDA enforcement visibility for the device firm as well. QA directors managing combination product supply chains should treat this correction as a prompt to audit the inspection history and CAPA status of any third-party drug component suppliers currently active in their approved supplier lists.

The FDA enforcement report for the Huons bupivacaine recall remains publicly accessible, and the BD correction is listed in the Medical Device Recall Database, providing a documented compliance trail that inspectors will reference against affected facilities' incoming material controls and supplier qualification records.

Source: FDA MedWatch Safety Alerts via FDA.gov, June 3, 2026.